# Treo Ventures

> Treo Ventures is a VC fund backing Health Care and Medical Device. See 13 investments, check sizes, portfolio and contact details. Updated Aug 2026.

- Type: VC Fund
- Location: Santa Clara, United States
- Total investments: 13
- Last investment: Nov 2025
- Lead investor: 62%
- Last updated: Aug 2026
- Website: https://treovp.com/

Treo Ventures is a VC fund in Santa Clara focused on Health Care and Medical Device. The S.H.I.P. team brings more than 50 years of cumulative healthcare experience in investing and operational roles. We have invested globally in more than 60 companies through multiple market cycles. We worked together on a number of healthcare investments over the last 12 years prior to forming S.H.I.P. We bring a unique set of investingexperiences from one of the largest strategic healthcare funds JJDC, which maintains a portfolio of over $1B and annually invests more than $200 million in medical devices, biotech, and consumer health, and private venture investing experiences at Synergy Life Science Partners, a top quartile performing venture capital fund.The S.H.I.P. team has been involved in some of the premium healthcare companies bringing novel technologies to market.

## Contacts

5 contacts available for Treo Ventures. Shizune tracks 3 team members at Treo Ventures. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-team-emails/strategic-healthcare-investment-partners?utm_source=investor_profile

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Health Care | 8 | 62% |
| Medical Device | 8 | 62% |
| Medical | 5 | 38% |
| Therapeutics | 2 | 15% |
| Biotechnology | 2 | 15% |

10 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series A | 5 | 38% |
| Series B | 2 | 15% |
| Series C | 2 | 15% |
| Series D | 2 | 15% |
| Private Equity | 1 | 8% |

6 stages tracked in total.

## Team

| Name | Title | Investments | Profile |
| --- | --- | --- | --- |
| Brad Vale | General Partner | 8 | https://shizune.co/investors/profile/brad-vale |
| Mudit Jain | Founding General Partner | 12 | https://shizune.co/investors/profile/mudit-jain |
| Tracy Pappas | Partner | 3 | https://shizune.co/investors/profile/tracy-pappas |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| iRiva Medical | iRiva Medical is developing novel neuromodulation therapies to address unmet therapeutic requirements in large patient populations. |  | Venture - Series Unknown | Nov 04, 2025 |  |
| SecondWave Systems | SecondWave Systems develops an ultrasound stimulation platform that will give patients and their physicians a new option for treating debilitating or life-threatening diseases. Their technology utilizes non-invasive, low-intensity focused ultrasound to modulate nerves, cells, and organs deep within the body. They provide technology that suppressesneural and cellular pathways with the potential to treat many conditions, including inflammation, pain, and a variety of other disorders. | $7M | Series A | Apr 08, 2025 |  |
| InterVene | InterVene is an up and coming medical device start-up company reinventing the way physicians treat severe venous disease in the legs. This technology represents the first-ever catheter-based, non-implantable approach, which allows physicians to create new vein valves for patients who are unable to efficiently pump blood out of their legs and backto their hearts. Millions of Americans currently suffer from painful venous stasis ulcers (VSU’s) and other costly and devastating symptoms, yet no therapy currently exists to solve one of the most prevalent underlying causes: deep vein valve failure. InterVene plans to change that.The company's mission is to provide the first effective and widely utilized therapy for patients suffering from the painful and costly symptoms of Chronic Venous Insufficiency (CVI) due to deep vein reflux (DVR). It was founded in 2011 and is based in South San Francisco, CA, USA. | $13M | Series A | Oct 07, 2024 |  |
| ShiraTronics | ShiraTronics is in the early stages of developing new innovative therapies to combat debilitating migraine headaches. The company is focused on commercializing novel neuromodulation technologies to treat this large unmet clinical need for patients and physicians. ShiraTronics is the first spinout from NuXcel a global medical device acceleratorcompany. | $66M | Series B | Sep 30, 2024 |  |
| NeuSpera Medical | NeuSpera Medical develops implantable medical device technology to treat chronic illnesses through minimally invasive solutions. NeuSpera focuses on bioelectronic medicine and has developed ultra-miniaturized implants using their proprietary Mid-Field Powering technology. This technology allows the implants to be powered externally, enabling deeperand more reliable neuromodulation treatments for conditions like Urinary Urgency Incontinence (UUI) and chronic peripheral nerve pain | $23M | Series D | Jul 15, 2024 |  |
| iVEAcare | iVEAcare develops innovative neuromodulation therapy to treat unmet clinical needs. | $27.5M | Series A | Apr 22, 2024 |  |
| Noctrix Health | Noctrix Health is an early-stage medical device company that focuses on developing a revolutionary therapy for a chronic illness. | $40M | Series C | Jan 16, 2024 |  |
| NeuSpera Medical | NeuSpera Medical develops implantable medical device technology to treat chronic illnesses through minimally invasive solutions. NeuSpera focuses on bioelectronic medicine and has developed ultra-miniaturized implants using their proprietary Mid-Field Powering technology. This technology allows the implants to be powered externally, enabling deeperand more reliable neuromodulation treatments for conditions like Urinary Urgency Incontinence (UUI) and chronic peripheral nerve pain | $65M | Series C | Jul 20, 2021 |  |
| Noctrix Health | Noctrix Health is an early-stage medical device company that focuses on developing a revolutionary therapy for a chronic illness. | $17M | Series B | Jan 11, 2021 |  |
| CVRx | CVRx is a medical device company that develops implantable technology for the treatment of high blood pressure. Its products include Rheos implantable pulse generator that provides control and delivery of the activation energy; and Rheos carotid sinus leads, which conducts activation energy from the Rheos implantable pulse generator to the left andright carotid arteries. The company also offers a Rheos programmer system that communicates with the Rheos pulse generator. CVRx was founded in 2001 and is based in Minneapolis, Minnesota. | $50M | Private Equity | Jul 07, 2020 |  |

10 of 13 investments shown.

## Co-investors
- [Action Potential Venture Capital](https://shizune.co/investors/profile/action-potential-venture-capital) — VC Fund, 3 deals together
- [Hatteras Venture Partners](https://shizune.co/investors/profile/hatteras-venture-partners) — VC Fund, 3 deals together
- [Vensana Capital](https://shizune.co/investors/profile/vensana-capital) — VC Fund, 3 deals together
- [Amzak Health Investors](https://shizune.co/investors/profile/amzak-health-investors) — VC Fund, 2 deals together
- [Aperture Venture Partners](https://shizune.co/investors/profile/aperture-venture-partners) — VC Fund, 2 deals together
- [New Enterprise Associates](https://shizune.co/investors/profile/new-enterprise-associates) — VC Fund, 2 deals together

## Similar investors

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund

## FAQ

### What does Treo Ventures invest in?

Treo Ventures invests primarily in Health Care, Medical Device and Medical startups, most often at Series A and Series B stage. Most of the 13 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### How do I contact Treo Ventures?

Public channels for Treo Ventures include the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### Who are the partners at Treo Ventures?

The team at Treo Ventures includes Brad Vale (General Partner), Mudit Jain (Founding General Partner) and Tracy Pappas (Partner). The Team section lists each member with their title, investment count and links.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co